ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...
CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor...
ModeX Therapeutics Inc, announces that the first participant has been dosed in the phase I trial (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed alongside Merck, referred to as MSD outside the U.S. and Canada...
The US Food and Drug Administration (FDA) released a draft guidance in collaboration with the Office for Human Research Protections that, once finalized, will offer suggestions for incorporating tissue biopsies into clinical trials. The draft...
Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405...
Hanx Biopharma, Inc. Ltd, a pioneering biotechnology firm focused on creating next-generation immunotherapies to tackle the challenges posed by unmet medical needs, announced the first patient dosing in Australia on December 30, 2024, for the...
The market for AI in clinical trials is fueled by the significant rate of clinical trial failures, the growing demand for predicting drug pharmacokinetics, pharmacodynamics, and toxicity management. The worldwide market for artificial intelligence...
The Clinical Trial Supplies market is driven by advanced technologies like blockchain and IoT in supply chain management. The market is projected to increase from US$2.70 Bn in 2024 to US$4.79 Bn by 2033, achieving a CAGR of 6.58% throughout the...
Lipella Pharmaceuticals Inc has reported the conclusion of dosing for the initial group in its multi-center phase 2a clinical trial for LP-310, a liposomal-tacrolimus oral rinse intended for treating oral lichen planus (OLP). In the initial group...
.jpg)
.jpg)
, CDSCO.jpg)